PTAFR

Across TCGA pan-cancer cohorts, PTAFR mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PTAFR data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PTAFR mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PTAFR expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and GBM are the cancer types where PTAFR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.679	0.243	.017	5	view →
LUAD	DFS	Quartile	III,IV	0.920	0.451	.035	3	view →
GBM	DFS	Tertile	All	0.503	0.249	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PTAFR–PDAC (DFS)

Open the PDAC breakdown →